We are live on ! Find out more
ACP

Acuta Capital Partners Portfolio holdings

AUM $142M
1-Year Est. Return 783.79%
This Fund
S&P 500
This Quarter Est. Return
+25.88%
1 Year Est. Return
+783.79%
3 Year Est. Return
+7,472.18%
5 Year Est. Return
+13,792.16%
10 Year Est. Return
+1,629,663.73%
AUM
$266M
AUM Growth
+$58.2M
Cap. Flow
+$10.2M
Cap. Flow %
3.84%
Top 10 Hldgs %
51.18%
Holding
88
New
23
Increased
18
Reduced
16
Closed
21

Top Buys

Rank Stock Value
1
AERI
Aerie Pharmaceuticals
AERI
+$6.17M
2
CEMI
Chembio diagnostics, Inc.
CEMI
+$5.47M
3
EVDY
Everyday Health, Inc.
EVDY
+$4.74M
4
ACAD icon
Acadia Pharmaceuticals
ACAD
+$4.54M
5
GWPH
GW Pharmaceuticals Plc American Depositary Shares
GWPH
+$3.97M

Top Sells

Rank Stock Value
1
RRM
RR MEDIA LTD ORD SHS (ISR)
RRM
+$8M
2
FOLD
Amicus Therapeutics
FOLD
+$3.32M
3
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$3.2M
4
MDVN
MEDIVATION, INC.
MDVN
+$3.02M
5
NDRM
NeuroDerm Ltd. Ordinary Shares
NDRM
+$2.96M

Sector Composition

Rank Sector Weight
1 Healthcare 68.34%
2 Technology 2.54%
3 Industrials 0.23%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BCRX icon
51
CALL
BioCryst Pharmaceuticals
BCRX
$2.24B
$473K 0.18%
+107,200
New +$428K
RIGL icon
52
CALL
Rigel Pharmaceuticals
RIGL
$693M
$367K 0.14%
+10,000
New +$287K
CRDF icon
53
PUT
Cardiff Oncology
CRDF
$72.7M
$359K 0.13%
1,111
+389
+54% +$142K
ARDX icon
54
Ardelyx
ARDX
$1.23B
$337K 0.13%
+26,076
New +$273K
PGNX
55
CALL
DELISTED
Progenics Pharmaceuticals Inc
PGNX
$253K 0.1%
+40,000
New +$242K
DXTR
56
DELISTED
Dextera Surgical Inc.
DXTR
$242K 0.09%
128,958
– –
BCRX icon
57
PUT
BioCryst Pharmaceuticals
BCRX
$2.24B
$223K 0.08%
+50,600
New +$202K
AKTX
58
Akari Therapeutics
AKTX
$12.9M
$197K 0.07%
29
-12
-29% -$93.6K
IMMU
59
CALL
DELISTED
Immunomedics Inc
IMMU
$190K 0.07%
58,600
– –
CBMX
60
DELISTED
CombiMatrix Corporation
CBMX
$133K 0.05%
47,431
– –
AGTC
61
DELISTED
Applied Genetic Technologies Corporation
AGTC
$100K 0.04%
+10,193
New +$137K
ONSIZ
62
DELISTED
Oncobiologics, Inc. Series B Warrant
ONSIZ
$97K 0.04%
96,833
– –
MNKD icon
63
PUT
MannKind Corp
MNKD
$1.17B
$56K 0.02%
18,000
– –
ONSIW
64
DELISTED
Oncobiologics, Inc. Series A Warrant Expiring 2/18/2019
ONSIW
$47K 0.02%
96,833
– –
PTX
65
PUT
DELISTED
Pernix Therapeutics Holdings, Inc.
PTX
$46K 0.02%
7,350
+1,070
+17% +$6.6K
RIGL icon
66
PUT
Rigel Pharmaceuticals
RIGL
$693M
$44K 0.02%
+1,190
New +$34.1K
AUDC icon
67
AudioCodes
AUDC
$249M
– –
-45,035
Closed -$189K
CDNA icon
68
CareDx
CDNA
$2.48B
– –
-64,627
Closed -$279K
CYTK icon
69
Cytokinetics
CYTK
$10.4B
– –
-140,969
Closed -$1.34M
INSM icon
70
Insmed
INSM
$21.3B
– –
-220,000
Closed -$2.17M
IRWD icon
71
Ironwood Pharmaceuticals
IRWD
$728M
– –
-59,700
Closed -$654K
NBIX icon
72
Neurocrine Biosciences
NBIX
$16.7B
– –
-42,000
Closed -$1.91M
OLED icon
73
Universal Display
OLED
$3.67B
– –
-15,000
Closed -$1.02M
PACB icon
74
Pacific Biosciences
PACB
$441M
– –
-300,000
Closed -$2.11M
PODD icon
75
Insulet
PODD
$11.8B
– –
-75,000
Closed -$2.27M
1 2
3
4

Similar funds

EC
EJF Capital Arlington, Virginia $142M AUM 23.3% 1-Year Est. Return
YEPX
Yorktown Energy Partners XI New York $142M AUM 130.51% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return
IA
IF Advisors San Antonio, Texas $141M AUM
MAM
Maytree Asset Management Hong Kong $141M AUM 114% 1-Year Est. Return
HA
HFG Advisors Cincinatti, Ohio $142M AUM 16.9% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
KCAM
Kagan Cocozza Asset Management Mickleton, New Jersey $142M AUM 12.02% 1-Year Est. Return

Acuta Capital Partners's Q3 2016 Portfolio in Review

As of Q3 2016, Acuta Capital Partners held 88 positions worth $266M, up 28% from $208M the previous quarter. Its ten largest holdings account for 51% of the portfolio.

Acuta Capital Partners deployed $10.2M of net new capital in Q3 2016, opening 23 new positions and adding to 18 existing holdings. Its largest new stake was Aerie Pharmaceuticals: 280,000 shares worth $10.6M.

By sector, the portfolio is most concentrated in Healthcare at 68% of assets, down from 73% a quarter earlier, followed by Technology and Industrials.

On the sell side, the largest reduction was Amicus Therapeutics, an estimated $3.32M trimmed.

  • Acuta Capital Partners's largest Q3 2016 buy was Aerie Pharmaceuticals: 280,000 shares worth $10.6M.
  • Acuta Capital Partners added most to Chembio diagnostics, Inc. in Q3 2016, an estimated $5.47M increase.
  • Acuta Capital Partners's biggest Q3 2016 reduction was Amicus Therapeutics, cutting an estimated $3.32M.
  • Acuta Capital Partners fully exited RR MEDIA LTD ORD SHS (ISR) in Q3 2016, selling an estimated $8M.
  • Acuta Capital Partners's ten largest holdings make up 51% of its $266M portfolio in Q3 2016.
  • Acuta Capital Partners opened 23 new positions and closed 21 in Q3 2016.
  • Acuta Capital Partners's portfolio value rose 28% quarter-over-quarter to $266M.

Based on Acuta Capital Partners's 13F filing for Q3 2016, filed 14 Nov 2016.